Contributions
Abstract: EP1451
Type: ePoster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Introduction: The incidence of multiple sclerosis (MS)-associated neoplasms was not a frequent report before the advent of immunomodulators (IMDs). In fact, it was assumed that MS granted a certain protective effect against the risk of developing cancer (Ca).
With the advent of IMDs, the potential association of MS with cancer events was first noted.
To date, the relationship between the impact of Ca and of cancer treatments with the progression of MS remains to be established.
PURPOSES: To analyze the characteristics of a group of patients with Demyelinating Diseases (DD) who developed cancer, the therapeutic behaviors and their progression.
Methods: We conducted a retrospective observational study of 1,192 patients with DD, and assessed 27 patients who developed cancer during the progression of their baseline disease. We evaluated the type of DD, the type of cancer, age at onset, treatments used, and progression of the DD within 2 years of cancer onset: presence of relapses, changes in the EDSS and MRI.
Results: n=27 patients with DD and Ca. Age at diagnosis: 28.9years and age at Ca onset: 47years. Clinical form: n: RRMS 21; SPMS 3; NMO 2; RIS 1.
IMDs: 21 patients. IMDs discontinued: 12 patients.
- n=cancer types: 6=breast; 5=thyroid; 7=gynecological; 3=colorectal; 2=skin; 4=others. 4=multiple.
- n=cancer therapy: 20=surgery; 7=chemotherapy; 3=radiotherapy; 8=combined; 1=none.
MS behavior in cancer patients:
- Relapses: 4=Yes; 14=No; 6=No data.
- Changes in EDSS: 2=Better; 14=No changes; 11=Worse (3=dead)
- Changes in MRI: 14=No changes; 3=New lesions; 10=No data
Conclusion: Only 4 patients had relapses after the development of cancer. Sixteen patients had the same or better scores at EDSS and over half of them evidenced MS progression in MRI. The coexistence of two potentially severe diseases (Ca and MS) would not necessarily involve a more unfavorable progression of MS.
Disclosure:
Curbelo, María Celeste: nothing to disclose.
Steinberg, Judith Diana: nothing to disclose.
Carrá, Adriana J: nothing to disclose.
Abstract: EP1451
Type: ePoster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Introduction: The incidence of multiple sclerosis (MS)-associated neoplasms was not a frequent report before the advent of immunomodulators (IMDs). In fact, it was assumed that MS granted a certain protective effect against the risk of developing cancer (Ca).
With the advent of IMDs, the potential association of MS with cancer events was first noted.
To date, the relationship between the impact of Ca and of cancer treatments with the progression of MS remains to be established.
PURPOSES: To analyze the characteristics of a group of patients with Demyelinating Diseases (DD) who developed cancer, the therapeutic behaviors and their progression.
Methods: We conducted a retrospective observational study of 1,192 patients with DD, and assessed 27 patients who developed cancer during the progression of their baseline disease. We evaluated the type of DD, the type of cancer, age at onset, treatments used, and progression of the DD within 2 years of cancer onset: presence of relapses, changes in the EDSS and MRI.
Results: n=27 patients with DD and Ca. Age at diagnosis: 28.9years and age at Ca onset: 47years. Clinical form: n: RRMS 21; SPMS 3; NMO 2; RIS 1.
IMDs: 21 patients. IMDs discontinued: 12 patients.
- n=cancer types: 6=breast; 5=thyroid; 7=gynecological; 3=colorectal; 2=skin; 4=others. 4=multiple.
- n=cancer therapy: 20=surgery; 7=chemotherapy; 3=radiotherapy; 8=combined; 1=none.
MS behavior in cancer patients:
- Relapses: 4=Yes; 14=No; 6=No data.
- Changes in EDSS: 2=Better; 14=No changes; 11=Worse (3=dead)
- Changes in MRI: 14=No changes; 3=New lesions; 10=No data
Conclusion: Only 4 patients had relapses after the development of cancer. Sixteen patients had the same or better scores at EDSS and over half of them evidenced MS progression in MRI. The coexistence of two potentially severe diseases (Ca and MS) would not necessarily involve a more unfavorable progression of MS.
Disclosure:
Curbelo, María Celeste: nothing to disclose.
Steinberg, Judith Diana: nothing to disclose.
Carrá, Adriana J: nothing to disclose.